High expression of PTX3 was associated with reduced progression‐free interval (PFI) and disease‐specific survival (DSS) in LGG and pan‐glioma samples in the TCGA dataset (Figure S2A,B). This evidence concerns the gene PTX3 and central nervous system cancer.